Gout, a painful joint condition, is on the rise globally, affecting even younger individuals. This surge is linked to ageing ...

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has ...

Creators on the video platform consistently underplayed the extent to which the disease is caused by underlying factors and ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

High uric acid levels can silently damage joints and kidneys if ignored. Knowing which foods worsen the condition can help prevent painful flare-ups.

For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...

Per the terms of the agreement, Sobi is expected to pay upwards of $950 million upfront in cash to acquire Arthrosi.The deal ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Discover often-missed early symptoms of high uric acid. From joint discomfort to fatigue, these warning signs can help you ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

Why do uric acid levels rise after festivals and holidays, and how can you control them naturally with diet and hydration ...